BRENTWOOD, Tenn. / Aug 28, 2024 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held September 4-6, 2024, in New York, NY.
Ardent Health President and Chief Executive Officer Marty Bonick and Chief Financial Officer Alfred Lumsdaine will take part in a fireside chat at the conference beginning at 10:00 a.m. ET on Thursday, September 5, 2024. A live audio webcast of the presentation will be available at the Investor Relations section of the Company’s website, at https://ir.ardenthealth.com, and a replay will be available for 90 days using the same link.
In conjunction with the conference, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend the conference. Interested investors should contact their Morgan Stanley representative to schedule meetings.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$16.61 |
Daily Volume: | 202,713 |
November 06, 2024 August 14, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load